Advances in Clinical Medicine
Vol. 11  No. 11 ( 2021 ), Article ID: 46652 , 8 pages
10.12677/ACM.2021.1111778

术前血清碱性磷酸酶水平对胸主动脉腔内修复术后疗效的预测价值

邓浩,邓泓博,池一凡*

青岛大学附属青岛市海慈医院心脏中心,山东 青岛

收稿日期:2021年10月19日;录用日期:2021年11月16日;发布日期:2021年11月23日

摘要

目的:探讨术前血清碱性磷酸酶(ALP)对胸主动脉腔内修复术(TEVAR)后疗效的预测价值。方法:回顾性分析2013年2月至2019年12月期间在我院接受TEVAR手术患者的临床资料。所有患者根据术前ALP水平,以中位数77.7 U/L为临界值分为低ALP水平组(第一组)和高ALP水平组(第二组)。比较两组患者术后复合事件的发生率,复合事件被定义为TEVAR术后1年内存在以下一种或多种情况:心肌梗死、脑血管意外、需要血液透析、肺部并发症、器官衰竭、感染和死亡,并逐步用Logistic回归分析评价复合事件发生率的预测因素。结果:两组复合事件的发生率分别是28.3%、45.1% (P = 0.002)。第二组ALP水平([OR] 1.393, 95%[CI] 1.049~1.735, P = 0.019)是复合事件发生率的独立预测因素。结论:在接受TEVAR的患者中,术前高ALP水平与不良结局间存在着独立的关系,这可能提示ALP作为危险分层有着潜在的作用。

关键词

胸主动脉腔内修复术,碱性磷酸酶,主动脉疾病,预测价值

The Predictive Value of Preoperative Serum Alkaline Phosphatase Level for Efficacy after Thoracic Endovascular Aortic Repair

Hao Deng, Hongbo Deng, Yifan Chi*

Department of Heart Center, HISER Medical Center of Qingdao Affiliated to Qingdao University, Qingdao Shandong

Received: Oct. 19th, 2021; accepted: Nov. 16th, 2021; published: Nov. 23rd, 2021

ABSTRACT

Objective: To explore the predictive value of preoperative serum alkaline phosphatase (ALP) level for efficacy after thoracic endovascular aortic repair (TEVAR). Methods: Clinical data of patients undergoing TEVAR in our hospital from February 2013 to December 2019 were retrospectively analyzed. All patients were divided into low ALP group (group 1) and high ALP group (group 2) according to preoperative ALP level and median 77.7 U/L as the critical value. The incidence of postoperative compound events was compared between the two groups, which were defined as the presence of one or more of the following: myocardial infarction, cerebrovascular accident, need hemodialysis, pulmonary complication, organ failure, infection and mortality within 1 year after TEVAR, and stepwise logistic regression analysis was performed to evaluate the predictors for compound events. Results: The incidence of compound events was 28.3% in group 1, 45.1% in group 2 (P = 0.002). The ALP level ([OR] 1.393, 95%[CI] 1.049~1.735, P = 0.019) in group 2 was an independent predictor of compound events. Conclusion: There is an independent relationship between high preoperative ALP levels and adverse outcomes in patients undergoing TEVAR, which may suggest a potential role of ALP level as a risk stratification.

Keywords:Thoracic Endovascular Aortic Repair, Serum Alkaline Phosphatase, Aortic Disease, Predictive Value

Copyright © 2021 by author(s) and Hans Publishers Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

1. 引言

胸主动脉腔内修复术(thoracic endovascular aortic repair, TEVAR)被认为是Stanford B型主动脉夹层的一线治疗方式,已逐渐取代传统开胸手术 [1]。其优势在于创伤小、并发症少、死亡率低,尤其适用于老年患者 [2],并发症也比开放手术要少得多 [3]。然而,行TEVAR的患者术前多合并其他疾病,且作为一种血管手术,本身有一定的缺陷。TEVAR术后围手术期发生脑梗死或一个月内发生脑血管不良事件的报道很少 [4]。有研究发现,缺血性心脏病和中风病史、严重的动脉粥样硬化、血清肌酐(Cr)水平升高是TEVAR术后的危险因素 [5],但都是非特异性的,且临床上较缺乏TEVAR术后远期疗效的分析。有人发现碱性磷酸酶(ALP)在调节动脉粥样硬化的过程中起到一定的作用 [6]。血清ALP水平在有肾病 [7]、高龄 [8]、心肌梗死(MI) [9]、脑卒中 [10] 的患者中,远期预后不良有较强的预测性 [11]。在接受经皮冠状动脉介入治疗(PCI)的患者中,血清ALP水平升高与术后不良事件的风险增加密切相关 [12]。考虑到血管系统的钙化可能影响主动脉疾病的远期预后,本研究旨在探究术前血清ALP水平对TEVAR术后远期疗效的预测价值。

2. 资料与方法

2.1. 一般资料

选取2013年2月至2019年12月,在我院行TEVAR手术患者453例,所有相关实验室指标由同一个人测量,手术由同一个团队进行。排除有创伤性主动脉损伤42例、合并有胆道系统结石和胆囊炎、脂肪肝等肝胆系统疾病患者83例、术前心肺复苏4例、1年内再次行主动脉手术史3例。最后对321例患者进行分析。根据所有患者术前血清ALP水平中位数将患者分为两组(第一组:ALP < 77.7 IU/L (n = 159),第二组:ALP ≥ 77.7 IU/L (n = 162))。患者对所有数据均知情同意,并获得本医院伦理委员会批准。

2.2. 观察指标

通过回顾患者诊疗记录、电话或门诊方式进行随访,平均随访11~15个月,平均(13 ± 2.6)个月。收集患者的基线特征包括性别、年龄、身高、体重、体重指数、合并症(高血压、糖尿病、冠状动脉闭塞性疾病(CAOD)、慢性阻塞性肺疾病(COPD)、脑血管意外和慢性肾病)、既往心血管药物服用史、吸烟。记录术前有无灌注不良(定义为出现内脏缺血的症状和体征)、术前射血分数、术前实验室检查(C-反应蛋白(CRP)、Cr、谷草转氨酶(AST)、谷丙转氨酶(ALT))。记录围手术期数据包括手术时间、术后即刻内漏。主要研究终点是以新发心肌梗死、中风、需要血液透析、肺部并发症、器官衰竭、感染及死亡,以及TEVAR术后15个月内这些复合事件终点的综合。感染定义为发生脓毒症、腹膜炎、尿路感染、移植物感染。

2.3. 统计学方法

采用R 3.6.1进行数据分析,GraphPad Prism 7进行绘图处理。在对正态分布进行Shapiro-Wilk检验之后,正态分布计量资料以均值 ± 标准差表示,非正态分布治疗采用四分位间距表示,组间比较采用独立样本t检验或Mann Whitney U检验;计数资料用频率和百分比表示,组间比较采用卡方检验或Fisher确切概率法。采用Logistic回归分析,评估分析组间比较差异有统计学意义(P < 0.2)的因素。多因素分析采用逐步筛选法,筛选出单因素分析中P < 0.2的变量。预测性用优势比(OR)和95%可信区间(CI)表示。P < 0.05被认为具有统计学意义。

3. 结果

1) 在研究期间,总共确认了453名患者,并对321名患者进行了最终分析。各组之间的基线特征具有可比性(表1)。

Table 1. Single factor analysis of preoperative baseline data of two groups

表1. 两组患者术前基线资料的单因素分析

注:BMI = 体重指数,BB = β受体阻滞剂,CCB = 钙通道阻断剂,RASI = 血管紧张素转换酶抑制剂,EF = 射血分数,IMH = 主动脉壁内血肿,PAU = 穿透性主动脉溃疡,HTN = 高血压,DM = 糖尿病。

2) 表2显示了围手术期数据,各个分区、分枝手术、急性肾损伤、手术时间、重症监护室住院时间、术后即刻内漏在两组间差异无统计学意义(P > 0.05)。

Table 2. Univariate analysis of perioperative data of two groups of patients

表2. 两组患者围手术期资料的单因素分析

注:AKI = 急性肾损伤。

3) 两组患者术后发生感染、器官衰竭、死亡、肺部并发症、血液透析、中风、心肌梗死的发病率终点均无显著差异(P > 0.05)。然而,在第二组中感染发生率较高,且复合终点事件的发生率比第一组高(45.1% > 28.3%, P = 0.002) (表3)。

Table 3. Univariate analysis of end points of compound events in two groups within 15 months after operation

表3. 两组患者术后15个月内复合事件终点的单因素分析

4) 身高、体重、BMI、既往高血压、是否吸烟、术前动脉瘤、术前Cr、术前AST、术前ALT、第二组ALP水平等因素在复合事件终点发生组比未发生复合事件终点发生组之间有显著差异(P < 0.2),并进行Logistic回归分析。各单因素森林图分布如图1所示。在单因素分析中选择是否吸烟、第二组ALP水平进行多因素分析。第二组ALP水平([OR] 1.393, 95%[CI] 1.049~1.735, P = 0.019)是复合事件终点的独立预测因素(表4)。

Figure 1. Single factor Logistic regression analysis of forest map

图1. 单因素Logistic回归分析森林图

Table 4. Logistic regression analysis of predictors of long-term outcome after TEVAR

表4. TEVAR术后远期疗效预测因素的Logistic回归分析

4. 讨论

我们回顾性分析了本院7年间321例行TEVAR手术患者的临床资料。结果表明,第二组患者感染、器官衰竭、肺部并发症、中风等复合事件终点的发生率均高于第一组。术前ALP水平较高,出现不良结局的可能性较大。因此,探讨行TEVAR患者术前ALP水平与术后不良结局的关系至关重要。

ALP是一种膜结合金属酶,催化有机焦磷酸盐的水解,有机焦磷酸盐是血管钙化的抑制剂 [13]。同时,ALP可通过水解动脉壁中的焦磷酸促进血管钙化 [13] [14]。因此,循环中的ALP水平可以指示血管钙化 [15]。血管钙化在血管老化和动脉粥样硬化过程中起重要作用,并且已知血管钙化的程度直接影响心血管疾病的发病率和死亡率 [16]。它与心肌梗死、心血管发病率和死亡率以及全因死亡有关。此外,主动脉弓和冠状动脉钙化与中风风险相关 [17]。ALP除了对患血管疾病的患者的自然病程和生存期有如此强的预测性之外。最新研究发现,血清ALP水平对接受经皮血运重建术的冠心病患者术后不良事件有潜在预测作用 [18]。与此一致,我们研究发现主动脉疾病患者行TEVAR术前ALP水平与不良的临床结果有着显著的关系。

众所周知,慢性肾功能衰竭是心血管疾病风险的一个很好的标志 [19]。然而,几乎所有患者慢性肾功能衰竭与炎症相关。低度慢性炎症中,CRP往往处于较高水平,而血清ALP水平的增加和CRP浓度有关 [20]。因此,炎症可能是高血清碱性磷酸酶水平和死亡率增加之间联系的另一个潜在机制 [21]。它的预测价值不仅在不考虑C-反应蛋白水平的情况下仍然显著,而且是对C-反应蛋白的预后信息的补充 [13]。据报道,与血清ALP活性升高相关的全身炎症状态可能会触发终末器官疾病的发展 [3]。我们的分析揭示了ALP水平和器官衰竭之间的双向关系,尽管没有统计学意义,但是值得进一步研究。

在本次研究中我们发现,感染是与ALP水平联系最密切的因素,尽管没有达到统计学意义(P = 0.081)。这可能与脓毒症相关死亡有关 [22]。目前ALP水平与感染易感性之间相互作用的确切病理生理机制尚不清楚,但据报道,病原诱导的ALP表达增加可触发Toll样受体4/NF-kB途径,导致促炎和抗炎细胞因子的产生 [23]。在这一方面,ALP是抑制还是激活炎症反应还有待研究。同时,我们观察到了高ALP水平与TEVAR术后远期不良结果有关,也证明了血清ALP水平在TEVAR术后远期疗效的预测价值。因此,对于术前ALP水平较高的患者,应密切关注术后并发症的发生情况,有助于患者长期生存。

这个研究有几点局限性。首先,本研究为回顾性研究,且纳入样本量偏少,因此存在一定的选择偏倚。两组之间发病终点没有显著差异也可能归因于样本量较小。其次,数据收集不全,如既往有无骨病、营养不良等没有包括在分析中,使得不得不排除在外而造成偏差,难以控制混杂因素。最后,随访时间不够,无法准确预测更长时间两组患者的预后。

5. 结论

综上所述,术前血清ALP水平与TEVAR术后不良结果相关;术前ALP水平可以作为TEVAR术后不良结局的预测因素。

基金项目

青岛市卫计委课题(2020-WJZD036),山东省医药卫生科技发展计划(202003011043),山东省中医药科技项目(2020Z30)。

文章引用

邓 浩,邓泓博,池一凡. 术前血清碱性磷酸酶水平对胸主动脉腔内修复术后疗效的预测价值
The Predictive Value of Preoperative Serum Alkaline Phosphatase Level for Efficacy after Thoracic Endovascular Aortic Repair[J]. 临床医学进展, 2021, 11(11): 5271-5278. https://doi.org/10.12677/ACM.2021.1111778

参考文献

  1. 1. 薛金熔, 李滨, 刘永民, 白涛, 潘旭东, 刘宁宁, 等. 急性主动脉夹层合并下肢缺血的外科治疗效果[J]. 中华医学杂志, 2017, 97(14): 1093-1095.

  2. 2. Garzon, G., Fernandez-Velilla, M., Marti, M., Acitores, I., Ybáñez, F. and Riera, L. (2005) Endovascular Stent-Graft Treatment of Thoracic Aortic Disease. RadioGraphics, 25, S229-S244. https://doi.org/10.1148/rg.25si055513

  3. 3. Haarhaus, M., Brandenburg, V., Kalantar-Zadeh, K., Stenvinkel, P. and Magnusson, P. (2017) Alkaline Phosphatase: A Novel Treatment Target for Cardiovascular Disease in CKD. Nature Reviews Nephrology, 13, 429-442. https://doi.org/10.1038/nrneph.2017.60

  4. 4. Acheampong, D.O., Paul, P., Guerrier, S., Boateng, P. and Leitman, I.M. (2018) Effect of Resident Involvement on Morbidity and Mortality Following Thoracic Endovascular Aortic Repair. Journal of Surgical Education, 75, 1575-1582. https://doi.org/10.1016/j.jsurg.2018.04.012

  5. 5. Tsubota, H., Sakaguchi, G. and Marui, A. (2019) Open and Endovascular Thoracic Aortic Repair in Patients with End-Stage Renal Disease. Interactive CardioVascular and Thoracic Surgery, 29, 761-765. https://doi.org/10.1093/icvts/ivz163

  6. 6. Pohl, S.O., Pervaiz, S., Dharmarajan, A. and Agostino, M. (2019) Gene Expression Analysis of Heat-Shock Proteins and Redox Regulators Reveals Combinatorial Prognostic Markers in Carcinomas of the Gastrointestinal Tract. Redox Biology, 25, Article ID: 101060. https://doi.org/10.1016/j.redox.2018.11.018

  7. 7. Li, X., Zhang, W., Liu, J., Gonzalez, L., Liu, D., Zhang, L., et al. (2020) Contrast-Induced Kidney Nephropathy in Thoracic Endovascular Aortic Repair: A 2-Year Retrospective Study in 470 Patients. Angiology, 71, 242-248. https://doi.org/10.1016/j.jvs.2014.04.051

  8. 8. Zakko, J., Scali, S., Beck, A.W., Klodell Jr., C.T., Beaver, T.M., Martin, T.D., et al. (2014) Percutaneous Thoracic Endovascular Aortic Repair Is Not Contraindicated in Obese Patients. Journal of Vascular Surgery, 60, 921-928. https://doi.org/10.1016/j.ejvs.2015.01.025

  9. 9. Faure, E.M., Canaud, L., Marty-Ane, C., Becquemin, J.P. and Alric, P. (2015) Endovascular Management of Rupture in Acute Type B Aortic Dissections. European Journal of Vascular and Endovascular Surgery, 49, 655-660. https://doi.org/10.1016/j.ejvs.2015.01.025

  10. 10. Scali, S.T., Wang, S.K., Feezor, R.J., Huber, T.S., Martin, T.D., Klodell, C.T., et al. (2014) Preoperative Prediction of Spinal Cord Ischemia after Thoracic Endovascular Aortic Repair. Journal of Vascular Surgery, 60, 1481-1490. https://doi.org/10.1016/j.jvs.2014.08.103

  11. 11. Ruan, Z.B., Zhu, L., Yin, Y.G. and Chen, G.-C. (2014) Risk Factors of Early and Late Mortality after Thoracic Endovascular Aortic Repair for Complicated Stanford B Acute Aortic Dissection. Journal of Cardiac Surgery, 29, 501-506. https://doi.org/10.1111/jocs.12377

  12. 12. Zapf, M.A.C., McEvoy, M.D., Brumley, M.T., Hamm, J. and Wanderer, J.P. (2020) Patients Able to Complete an Online Preoperative Screening Tool Are Younger, but Have Similar Comorbid Status and Health Literacy. Journal of Clinical Anesthesia, 64, Article ID: 109802. https://doi.org/10.1016/j.jclinane.2020.109802

  13. 13. Schoppet, M. and Shanahan, C.M. (2008) Role for Alkaline Phosphatase as an Inducer of Vascular Calcification in Renal Failure? Kidney International, 73, 989-991. https://doi.org/10.1038/ki.2008.104

  14. 14. Lomashvili, K.A., Garg, P., Narisawa, S., Millan, J.L., O’Neill, W.C. (2008) Upregulation of Alkaline Phosphatase and Pyrophosphate Hydrolysis: Potential Mechanism for Uremic Vascular Calcification. Kidney International, 73, 1024-1030. https://doi.org/10.1038/ki.2008.26

  15. 15. Gao, S., Ren, Y., Zhang, H., Pan, B. and Gao, H. (2016) Identification and Expression Analysis of IκB and NF-κB Genes from Cyclina sinensis. Fish & Shellfish Immunology, 56, 427-435. https://doi.org/10.1016/j.fsi.2016.07.035

  16. 16. Lomashvili, K.A., Cobbs, S., Hennigar, R.A., Hardcastle, K. and O’Neill, W.C. (2004) Phosphate-Induced Vascular Calcification: Role of Pyrophosphate and Osteopontin. Journal of the American Society of Nephrology, 15, 1392-1401. https://doi.org/10.1097/01.ASN.0000128955.83129.9C

  17. 17. Iribarren, C., Sidney, S., Sternfeld, B. and Browner, W.S. (2000) Calcification of the Aortic Arch: Risk Factors and Association with Coronary Heart Disease, Stroke, and Peripheral Vascular Disease. JAMA, 283, 2810-2815. https://doi.org/10.1001/jama.283.21.2810

  18. 18. Oh, P.C., Lee, K., Kim, T.H., Moon, J., Park, H.W., Jang, H.-J., et al. (2017) Prognostic Impact of Alkaline Phosphatase Measured at Time of Presentation in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. PLoS ONE, 12, Article ID: e171914. https://doi.org/10.1371/journal.pone.0171914

  19. 19. Ridker, P.M., Rifai, N., Rose, L., Buring, J.E. and Cook, N.R. (2002) Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. New England Journal of Medicine, 347, 1557-1565. https://doi.org/10.1056/NEJMoa021993

  20. 20. Kerner, A., Avizohar, O., Sella, R., Bartha, P., Zinder, O., Markiewicz, W., et al. (2005) Association between Elevated Liver Enzymes and C-Reactive Protein: Possible Hepatic Contribution to Systemic Inflammation in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 193-197. https://doi.org/10.1161/01.ATV.0000148324.63685.6a

  21. 21. Beddhu, S., Ma, X., Baird, B., Cheung, A.K. and Greene, T. (2009) Serum Alkaline Phosphatase and Mortality in African Americans with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology, 4, 1805-1810. https://doi.org/10.2215/CJN.01560309

  22. 22. Abramowitz, M., Muntner, P., Coco, M., Southern, W., Lotwin, I., Hostetter, T.H., et al. (2010) Serum Alkaline Phosphatase and Phosphate and Risk of Mortality and Hospitalization. Clinical Journal of the American Society of Nephrology, 5, 1064-1071. https://doi.org/10.2215/CJN.08621209

  23. 23. Peters, E., Heemskerk, S., Masereeuw, R. and Pickkers, P. (2014) Alkaline Phosphatase: A Possible Treatment for Sepsis-Associated Acute Kidney Injury in Critically Ill Patients. American Journal of Kidney Diseases, 63, 1038-1048. https://doi.org/10.1053/j.ajkd.2013.11.027

  24. NOTES

    *通讯作者。

期刊菜单